万赛维好用吗？

It is an oral anti-cytomegalovirus infection drug developed by Roche of Switzerland and launched in my country in 2006. It is suitable for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis and the prevention of CMV infection in high-risk solid organ transplant patients.

Vancevir is an oral medication and should be taken with food. The recommended dose for induction treatment of CMV retinitis in adults is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity. After induction therapy, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis.

How effective is Vancevi in treatment?

The U.S. Food and Drug Administration (FDA) has approved the increased use of Vancevir in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease. The supplemental approval is based on data that longer-term prophylaxis with Vancevir reduced the incidence of CMV disease in high-risk adult renal transplant patients from 36.8% (for patients who received 100 days of therapy) to 16.8% (for patients who received 200 days of therapy at one year after receiving a kidney transplant) (p < 0.0001). 1.2 The overall safety profile of Vancevir did not change when prophylaxis was extended in high-risk renal transplant patients.

Clinical studies conducted in AIDS patients infected with CMV retinitis have shown that Vancevir tablets and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the Vancevir tablet group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week 4 was the same in both groups. After induction therapy, both groups of patients in the study continued to receive maintenance therapy with Vancevir tablets at a dose of 900 mg per day. Among patients who received Vancevir tablets or intravenous ganciclovir induction therapy followed by Vancevir tablets maintenance therapy, the mean (median) time from randomization to progression of CMV retinitis was: 226 (160) days and 219 (125) days.